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Abstract: In this study, curcumin-loaded porous poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(NPs) were prepared and surface modified with red blood cell membranes (RBCM) to yield biomimetic
RBCM-p-PLGA@Cur NPs. The NPs displayed a visible cell-membrane structure at their exterior
and had a uniform size of 162 ± 3 nm. In vitro studies showed that drug release from non-porous
PLGA NPs was slow and that much of the drug remained trapped in the NPs. In contrast, release was
accelerated from the porous PLGA NPs, and after the RBCM coating, a sustained release over 48 h was
obtained. Confocal microscopy and flow cytometry results revealed that the RBCM-p-PLGA NPs led
to a greater cellular uptake by H22 hepatocarcinoma cells than the uncoated analogue NPs, but could
avoid phagocytosis by macrophages. The drug-free formulations were highly biocompatible, while
the drug-loaded systems were effective in killing cancer cells. RBCM-p-PLGA@Cur NPs possess
potent anti-tumor activity in a murine H22 xenograft cancer model (in terms of reduced tumor volume
and mass, as well as inducing apoptosis of tumor cells), and have no observable systemic toxicity.
Overall, our study demonstrates that the use of the RBCM to cloak nanoscale drug delivery systems
holds great promise for targeted cancer treatment, and can ameliorate the severe side effects currently
associated with chemotherapy.
Keywords: erythrocyte membrane; porous PLGA nanoparticle; curcumin; anticancer therapeutics
1. Introduction
Despite many recent therapeutic innovations, it remains the case that cancer imposes a major
disease burden worldwide. Traditional methods of treatment include surgery, chemotherapy, and
radiation therapy. However, it is not possible to surgically resect all tumors, and chemotherapy is
associated with severe off-target effects. Major research efforts are underway to develop effective and
non-toxic drug carriers able to target therapy specifically to tumor tissue, and thus to ameliorate these
challenges in the treatment of cancer [1,2].
There exist a number of approaches that can be used to achieve such targeting. The simplest
involves passive targeting, relying on the build-up of a drug delivery system (DDS) in the tumor
because of its leaky vasculature [3]. Active targeting can also be realized; this has mostly been achieved
by functionalizing particles with ligands to membrane receptors over-expressed on cancer cells, thus
aiding specific uptake of a formulation by the target cell population [4–7]. Biomimetic systems have
also been developed, with the aim of improving circulation times, avoiding an immune response,
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and/or increasing targeting specificity [8]. The latter approach involves attempting to disguise DDSs as
endogenous cells or molecules [9].
Red blood cells (RBCs, otherwise known as erythrocytes) comprise the most abundant population of
cells in the blood, and have attracted increasing attention in medicines development [10,11]. RBCs have
extended systemic circulation times [12], and being endogenous cells are highly biocompatible with
low immunogenicity. They can also be used in the development of DDSs, and using the RBC membrane
(RBCM) to cloak nanoparticle DDSs has been deemed an effective approach to developing improved
therapeutics [13,14]. The presence of the protein CD47 on the RBCM regulates macrophage uptake by
interacting with the CD47 receptor-signaling protein on the surface of the latter [15]. Consequently,
RBCM-coated materials can act as effective drug carriers in vivo, avoiding phagocytosis and persisting
in the systemic circulation for a long period of time.
There are myriad of compounds reported to have anti-cancer activity. One which has been
especially widely explored is curcumin (Cur) [16], a phenolic pigment extracted from the rhizome
of Curcuma longa. Cur has been found to have a wide range of pharmacological activities, including
anti-inflammatory and anti-oxidant effects [17]. In addition, it inhibits tumor growth [18,19], lowers
blood cholesterol levels [20], promotes wound healing [21], and also has immunomodulation [22],
antibacterial [23] and anti-fibrotic effects [24]. However, there are a number of obstacles that need to be
overcome before it can be widely used in therapeutic applications: Cur has low stability, poor water
solubility, low bioavailability, and undergoes rapid in vivo metabolism. As a result, novel drug delivery
systems able to circumvent these issues are needed.
The use of nanoparticulate carriers is one approach that has long been used to improve the
pharmacokinetics of anticancer drugs, including Cur [25]. These can be fabricated from a wide range of
materials, with the polymer poly(lactic-co-glycolic acid) (PLGA) having been particularly extensively
studied [26]. PLGA is approved for use in humans by the United States Food and Drug Administration,
since it has low toxicity and tunable biodegradability. However, drug release from monolithic PLGA
nanoparticles is often slow, lasting weeks or months [27]. For anti-cancer applications, a more rapid
release profile is likely to be required. To solve this problem, porous PLGA nanoparticles can be
generated to accelerate drug release [28]. Vitamin E TPGS (TPGS) is one species which can be used to
induce pore formation, and it has been found that the drug release profile can be tuned by adjusting
the component ratio between PLGA and TPGS [29–31].
In this work, we developed a drug delivery system using the RBCM to cloak porous PLGA
nanoparticles loaded with Cur (RBCM-p-PLGA@Cur NPs), and explored their effect on H22 cancer
cells both in vitro and in vivo in an xenograft mouse model (Scheme 1).
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Scheme 1. Schematic illustration of the preparation of the RBCM-p-PLGA@Cur NPs, and their
anti-tumor effects. Abbreviations: RBC, red blood cell; RBCM, red blood cell membrane; Cur, curcumin;
p-PLGA, porous poly(lactic-co-glycolic acid) nanoparticles; p-PLGA@Cur NPs, curcumin-loaded porous
poly(lactic-co-glycolic acid nanoparticles); RBCM-p-PLGA@Cur NPs, red blood cell membrane cloaked
curcumin-loaded porous poly(lactic-co-glycolic acid) nanoparticles.
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2. Materials and Methods
2.1. Materials and Reagents
PLGA (lactide:glycolide ratio = 50:50, Mw = ~21,000) was purchased from Jinan Daigang
Biological Engineering Co., Ltd. (Jinan, China). Cur and vitamin E TPGS (TPGS) were
sourced from Aladdin (Shanghai, China). Hoechst 33342 dye, ethylenediamine, triethylamine,
N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
(EDC·HCl), dimethylsulfoxide (DMSO), 4-dimethylaminopyridine (DMAP), fluoresceinisothiocyanate
(FITC) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). A membrane protein extraction kit and protease inhibitor were
procured from Phygene Life Sciences (Fuzhou, China), and a Pierce BCA protein assay kit from Life
Technologies (Hudson, NH, USA). Trypsin, fetal bovine serum (FBS), RPMI-1640 medium, penicillin,
streptomycin and phosphate buffered saline (PBS, pH = 7.4) were obtained from Gibco (Carlsbad, CA,
USA). H22 cells (a murine hepatocellular carcinoma cell line), 4T1 cells (a mouse breast adenocarcinoma
cell line), L929 cells (a mouse fibroblast cell line) and RAW264.7 (macrophage) cells were provided
by the Institute of Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai,
China). All chemicals and reagents were used as received. Deionized water (H2O) was purified with a
Millipore system (Milli-Q, 18.2 MΩ cm, Burlington, MA, USA).
2.2. Preparation and Characterization of p-PLGA NPs
Blank porous PLGA NPs (p-PLGA NPs) were prepared using the nanoprecipitation method,
as described previously [31]. A total of 10 mg PLGA and 2 mg TPGS were dissolved in 1 mL acetone.
The solution was sonicated until complete dissolution was achieved, and then added dropwise into
5 mL of deionized water under stirring at 1000 rpm. After leaving the suspension to stand for 3 h to
evaporate the acetone [32], 500 µL of the resulting NP suspension was set aside for electron microscopy,
dynamic light scattering (DLS) and zeta potential analysis, and the rest was stored at 4 ◦C for further use.
2.3. Loading of Cur
For the preparation of p-PLGA@Cur NPs, 100 mg PLGA, 20 mg TPGS and 10 mg of Cur were
dissolved in 10 mL acetone. The solution was sonicated until complete dissolution was achieved,
and then added dropwise into 50 mL of deionized water under stirring at 1000 rpm. After 3 h, the
obtained suspension was centrifuged at 12,000 rpm for 15 min to remove unloaded Cur. The supernatant
was 10-fold diluted with methanol and a UV-vis spectrophotometer (UNICO, Shanghai, China) used to
quantify the Cur loading. The Cur concentration was calculated based on a pre-determined calibration
curve. The Cur encapsulation efficiency (EE %) and loading content (LC %) were determined as follows:
Mass of Cur in NPs = total mass of Cur in feed −mass of Cur in the supernatant
Total mass of NPs = mass of polymer + mass of Cur in NPs
EE% =
mass of Cur in NPs
total mass of Cur in feed
× 100%
LC% =
mass of Cur in NPs
total mass of NPs
× 100%
2.4. Isolation of RBCM
Cells were extracted from fresh whole mouse blood, and then transferred into an anticoagulant-coated
tube [14,33,34]. First, the blood was centrifuged at 3000 rpm for 5 min at 4 ◦C to remove the plasma
and leukocytes, then washed with phosphate buffered saline (PBS, pH = 7.4) three times. The RBCs
obtained were resuspended in a 0.2 mM solution of EDTA in water, to induce membrane rupture.
The hemoglobin released was removed by centrifugation at 14,800 rpm for 7 min at 4 ◦C. The resultant
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pellet was resuspended in 0.2 mM EDTA and centrifuged again. The EDTA/centrifugation steps were
repeated until the supernatant was clear and colorless. Finally, the RBCMs were suspended in PBS
(pH = 7.4) containing 0.1 mg/mL of a protease inhibitor and stored at −80 ◦C for further use.
2.5. Preparation and Characterization of RBCM-p-PLGA@Cur NPs
RBCM-p-PLGA NPs were prepared following a literature protocol [35,36]. Briefly, 2 mL of a
2 mg/mL suspension of p-PLGA NPs was mixed with RBCM derived from 500 µL of whole blood
under magnetic stirring for 10 min. This mixture was then ultrasonicated at 100 W for 5 min. Finally,
RBCM-p-PLGA NPs were obtained after the suspension was extruded repeatedly through 200 nm
polycarbonate membranes. To prepare RBCM-p-PLGA@Cur NPs, the same procedure was performed
using p-PLGA@Cur NPs as the starting material. The hydrodynamic particle size and zeta potential of
the RBCM coated nanoparticles were measured using a Zetasizer (Malvern Instruments, Westborough,
MA, USA) and their morphology was characterized by TEM. The colloidal stability of the nanoparticles
was verified using a Zetasizer. Experiments were performed at 25 ◦C in different media, including
Milli-Q water and PBS.
To further verify successful coating of RBCM on p-PLGA NPs, the membrane proteins in RBCM
and RBCM-p-PLGA NPs were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). Samples were lysed in a SDS buffer and then processed with a BCA assay kit to determine
the total protein concentrations. The lysates were then run on a 4–12% Bis-Tris 10-well minigel in a
running buffer, using a BIO-RAD electrophoresis system (80 V, 2 h, BIO-RAD, CA, USA). The resulting
polyacrylamide gel was stained with Coomassie brilliant blue for 1 h to permit visualization of the
protein bands.
2.6. Characterization Techniques
Zeta potential and dynamic light scattering (DLS) were quantified at 25 ◦C with the aid of a
Zetasizer Nano ZS system (Malvern Instruments, Westborough, MA, USA). Transmission electron
microscopy (TEM) images were recorded using a JEOL 2010F transmission electron microscope (Hitachi,
Tokyo, Japan), while field emission scanning electron microscopy (FESEM) images were captured on a
JEOL S-4800 instrument (Hitachi, Tokyo, Japan). UV-vis spectra were recorded at 25 ◦C on a UV-1800
spectrophotometer (UNICO, Shanghai, China). Confocal laser scanning microscopy (CLSM) images
were collected on a LSM 700 microscope (Carl Zeiss, Jean, Germany). Flow cytometry analysis was
performed on a flow cytometer (Becton Dickinson, CA, USA).
2.7. Drug Release
For control purposes, non-porous PLGA NPs loaded with Cur (PLGA@Cur NPs) were generated.
The preparation method was the same as described for p-PLGA@Cur, except that TPGS was not added.
The release of Cur from the NPs was then evaluated using a dialysis method. A total of 2.0 mL of
2 mg/mL suspensions of PLGA@Cur, p-PLGA@Cur or RBCM-p-PLGA@Cur NPs were loaded into a
dialysis bag (MWCO = 7,000 Da), and immersed in PBS (18.0 mL, pH 7.4). The samples were placed
in a incubator at 37 ◦C with shaking (100 rpm). Light was excluded throughout the experimental
period of 48 h. Periodically, 1 mL aliquots were taken from the external medium and replaced with an
equal volume of fresh pre-heated buffer. The concentration of Cur released was measured by UV-vis
spectroscopy at λmax of 425 nm. Data are reported as mean ± standard deviation (S.D.), n = 4.
2.8. Cytotoxicity Measurements
An in vitro cytotoxicity investigation was performed to evaluate the biocompatibility of blank
p-PLGA and RBCM-p-PLGA NPs with L929 cells and H22 cells [37]. Cells were cultured in
RPMI-1640 medium supplemented with penicillin (100 µg/mL), streptomycin (100 µg /mL), and 10%
v/v heat-inactivated fetal bovine serum (FBS). 200 µL of cell suspension was seeded in each well of a
96-well plate (1 × 104 cells/well) and incubated at 37 ◦C under a 5% CO2 atmosphere for 24 h.
Pharmaceutics 2019, 11, 429 5 of 16
For biocompatibility experiments, the medium was removed from the cells and 200 µL of
fresh medium containing different concentration of p-PLGA or RBCM-p-PLGA NPs (5, 10, 20, 50,
80, 100, 200, 500 µg/mL) was added to each well, before the cells were cultured for another 24 h.
For cytotoxicity experiments, after removal of the initial medium, 200 µL of fresh medium containing
different concentrations of free Cur (2.5, 5, 10, 20, 30, 40, 50, 100 µg/mL), or p-PLGA@Cur or
RBCM-p-PLGA@Cur NPs (giving equivalent drug concentrations) was added to each well, before
the cells were cultured for a further 24 h. After that, the medium was aspirated and 20 µL of MTT
solution (5 mg/mL) and 180 µL of fresh medium was added to each well. The plate was incubated for
an additional 3 h in darkness. The medium was then removed, 200 µL of DMSO was added to each
well, and the plate was shaken at 100 rpm for 15 min. The absorbance of the wells was finally measured
at 570 nm, using a microplate reader (Multiskan FC, Thermo Scientific, Hudson, NY, USA). The relative
cell viability was calculated relative to an untreated cells control. Data are reported as mean ± S.D.
Three independent experiments each containing three replicate wells per condition were performed.
2.9. Cellular Uptake
In order to track the distribution of the RBCM-p-PLGA NPs visually, FITC was employed to
label the PLGA NPs. To prepare labeled NPs, a total of 300 mg of PLGA, 1.8 mg of NHS, 2.9 mg of
EDC and 1 mg of DMAP were dissolved in 10 mL of dichloromethane and stirred for 24 h at 25 ◦C
to convert PLGA to PLGA-NHS. Afterward, 1.8 mg of ethylenediamine and 8.6 µL of triethylamine
were added to the solution, which was stirred for another 3 h. Subsequently, 35 mg of FITC was
added into the solution and stirring was performed for a further 12 h at 25 ◦C. A rotary evaporator
was used to remove the dichloromethane, and 5 mL of N,N-dimethylformamide (DMF) added to
dissolve the conjugate. The resultant solution was placed into a dialysis bag (MWCO = 7000 Da) and
dialyzed against water for 3 days to remove unreacted FITC. Finally, the product was freeze-dried for
48 h to obtain FITC-PLGA. The resultant FITC-PLGA was then used to prepare labeled p-PLGA NPs
(FITC-p-PLGA NPs) and RBCM coated FITC labeled PLGA NPs (RBCM-FITC-p-PLGA NPs) using the
same procedure as described above.
The uptake of FITC-p-PLGA NPs and RBCM-FITC-p-PLGA NPs was observed using CLSM [38].
A total of 200 µL of a RAW 264.7, H22 cell or 4T1 cell suspension (5 × 104 cells/well) and 800 µL of
complete medium were added to each well of a 24-well cell culture plate and incubated at 37 ◦C under a
5% CO2 atmosphere for 24 h. After aspiration of the medium, the cells were treated with 900 µL of fresh
medium and 100 µL of PBS or 2 mg/mL FITC-p-PLGA NPs or RBCM-FITC-p-PLGA NP suspensions.
Following incubation for another 2 h, the cells were washed twice with PBS, and 1 mL of glutaraldehyde
(2.5%) was added and the cells kept for 15 min at 4 ◦C. This was followed by counterstaining with
0.5 mL Hoechst 33342 (10 µg/mL) for 15 min at 37 ◦C. Finally, images were obtained by CLSM.
For flow cytometry analysis, 2.4 mL of a H22 cell or RAW 264.7 suspension (containing 1× 105 cells)
was placed in each well of a 6-well cell culture plate and incubated at 37 ◦C under a 5% CO2 atmosphere
for 24 h. After removal of the medium, 2 mL of fresh RPMI and 500 µL of PBS or suspensions of
FITC-p-PLGA or RBCM-FITC-p-PLGA NPs (200 µg/mL) were added, and the cells cultured for 4 h.
The cell pellet was collected by centrifugation at 1100 rpm for 3 min, the supernatant discarded, and the
pellet dispersed in 500 µL of PBS. Cellular uptake was determined by flow cytometry.
2.10. In Vivo Murine Tumor Model
All animal experiments were undertaken with full authorization from the Committee for
Experimental Animal Welfare and Ethics of Yunnan University of Traditional Chinese Medicine.
(project identification code: R-062019031, approval date: 11 March 2019). A total of 20 ICR female
mice (specific pathogen-free grade, 18–20 g) were acquired from Jiangsu KeyGEN BioTECH Co. Ltd.,
Jiangsu, China. Tumors were implanted by subcutaneous injection into the right front limb armpit of
each mouse of 1 × 106 H22 cells in 100 µL of PBS (pH 7.2–7.4).
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2.11. In Vivo Antitumor Efficacy
After H22 cell implantation, the tumors were allowed to grow until their volume (calculated
as 0.5 × length × diameter2) reached ca. 120 mm3. The mice were then randomly divided into four
groups (5 mice per group). Each mouse was intravenously injected, via the tail vein, with PBS, free Cur
(dissolved in 1% DMSO), p-PLGA@Cur NPs or RBCM-p-PLGA@Cur NPs (at a Cur dose of 2 mg/kg)
every two days for 16 days. The tumor volumes and body weight were recorded every two days.
After 16 days, all the mice were sacrificed by cervical vertebra dislocation. The heart, liver, spleen,
lung, kidney and tumor of the mice were immediately excised and washed with physiological saline.
The tissues were fixed with a 4% aqueous paraformaldehyde solution and embedded in paraffin
for sectioning. The sliced organ tissues (thickness: 4 mm) were mounted on glass slides, stained by
hematoxylin and eosin (H&E) [39,40] and imaged with a Nikon DS-U3 digital microscope (Nikon,
Tokyo, Japan). Tumor tissues were subjected to terminal deoxynucleotidyl transferase (TdT) mediated
dUTP-digoxigenin nick end labeling (TUNEL) staining according to the manufacturer’s instructions,
and images were obtained using a Pannoramic 250 digital scanner (PerkinElmer, Boston, MA, USA).
2.12. Statistical Analysis
Differences between two groups were analyzed by Student’s t test and mean values were compared
via one-way ANOVA; the significance level was defined as p < 0.05, with * denoting p < 0.05, ** p < 0.005
and *** p < 0.001.
3. Results and Discussion
3.1. Characterization of NPs
The p-PLGA nanoparticles were found to be spherical in shape by TEM (Figure 1a). Their size
was 139 ± 11 nm (Figure 1b). However, any porous structure was unclear due to the small size
of the particles and limitations in the resolution of the microscope. To check for porosity, larger
nanoparticles were thus prepared using the same methodology but with a slower stirring speed of
300 rpm (see Supplementary Materials, Figure S1). Under these conditions the porous structure
was clearly seen, and thus it can be concluded that the use of TPGS permitted porous particles to
be produced. After the RBCM coating, a membrane structure was visible around the p-PLGA NPs,
with an outer lipid bilayer shell ≈ 16 nm in thickness (Figure 1c). The particles increased in size to
169 ± 8 nm (Figure 1d).
DLS revealed that the hydrodynamic size of the RBCM-p-PLGA NPs was 162 ± 3 nm (Figure 1e)
and that they had a low polydispersity index (PDI = 0.102). They were somewhat larger and
more polydisperse than the bare p-PLGA NPs (138 ± 4 nm, PDI = 0.047). As shown in Figure 1f,
the RBCM-p-PLGA@Cur NPs exhibited excellent colloidal stability, and could be dispersed in both
water and PBS without aggregation over time. The zeta potential decreased from −28.4 ± 1.4 mV
with p-PLGA to −34.3 ± 1.2 mV after RBCM coating (Figure 1g), similar to the potential of the RBCM
precursor. A more negative zeta potential arose with the RBCM owing to the presence of anionic
phospholipid head groups at the two exterior sides of the membrane. One side of this interacted
favorably with the PLGA, while the other side formed hydrogen bonds with the water continuous phase.
To verify the presence of an intact RBCM coating, we subjected the RBCM-p-PLGA NPs,
to SDS-PAGE gel electrophoresis (Figure 1h). The RBCM-p-PLGA NPs displayed almost identical
gels to the RBCM, confirming that they contained the same protein components and that the RBCM
was preserved in the NPs. Taken together, all these data allow us to conclude that the p-PLGA NPs
were successfully coated with a RBCM layer. The observations noted here are in line with those in the
literature [13,14].
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(c) RBCM-p-PLGA NPs, together with (b,d) their respective size distributions and (e) dynamic
light scattering (DLS) data. (f) The sizes of RBCM-p-PLGA@Cur NPs stored in water and PBS,
as determined by DLS. (g) Zeta-potential data. (h) SDS-PAGE analysis of RBCM and the RBCM-p-PLGA
NPs. In (f,g) data are shown as mean ± S.D. (n = 3).
3.2. Drug Loading and Release Behavior
UV-vis absorption spectra of p-PLGA and the p-PLGA@Cur NPs are shown in Figure S2.
A distinctive peak at around 260 nm, seen in both spectra, was attributed to the presence of PLGA.
A characteristic peak from Cur at 425 nm was also observed for the p-PLGA@Cur NPs. These results
suggested successful encapsulation of Cur. The EEs of the PLGA@Cur and p-PLGA@Cur NPs were
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found to be 97.3 ± 1.2% and 93.8 ± 1.5%, and the drug loadings 8.9 ± 0.8% w/w and 8.6 ± 0.6%
w/w, respectively.
The in vitro drug release profiles of the PLGA@Cur, p-PLGA@Cur and RBCM-p-PLGA@Cur NPs
are given in Figure 2. The percentage of Cur released from the NPs after 48 h reached 80.8 ± 4.5%
(≈139 µg) and 71.0 ± 4.3% (≈ 122 µg) for the p-PLGA NPs and RBCM-p-PLGA NPs, respectively,
significantly higher than that from the monolithic PLGA NPs (28.3± 4.6%) (≈ 50µg). The RBCM-p-PLGA
NPs exhibited sustained release over 48 h. This prolonged release (cf. the p-PLGA@Cur NPs) can be
attributed to the RBCM coating, which serves as a diffusional barrier to Cur release.
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The mechanism of drug release was explored using the Peppas equation [41]:
Q = ktn.
Q is the percentage of drug released at a given time, t is the rele e tim , k is a rate co stant,
and n is an exponent that indicates the drug release mechanis . The outcome of this analysis are
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around 980 h, 34 h, and 68 h for 100% release to be attained from the PLGA@Cur, p-PLGA@Cur and
RBCM-p-PLGA@Cur NPs, respectively.
3.3. In Vitro Cytotoxicity
The biocompatibility of the blank p-PLGA NPs and RBCM-p-PLGA NPs was evaluated by MTT
analysis using L929 and H22 cells. As depicted in Figure 3a, both the p-PLGA and RBCM-p-PLGA NPs
had minimal effect on the viability of the cells. The cell viability was more than 85%, even at p-PLGA
and RBCM-p-PLGA NP concentrations of up to 500 µg/mL. The materials can thus be said to be
highly biocompatible. Data on the in vitro cytotoxicity of the drug-loaded formulations on cancerous
H22 cells are presented in Figure 3b. The half maximal inhibitory concentrations (IC50) of free Cur,
p-PLGA@Cur NPs and RBCM-p-PLGA@Cur NPs to H22 cells were calculated to be 6.1 ± 0.5 µg/mL,
10.2 ± 0.8 µg/mL and 15.9 ± 1.3 µg/mL, respectively. When the Cur concentration was below 30 µg/mL,
it appears that free Cur and the p-PLGA@Cur NPs were more toxic than the RBCM-p-PLGA@Cur NPs,
which is likely a result of the sustained release of Cur caused by the RBCM shell. However, at Cur
dosages above 50 µg/mL the RBCM-p-PLGA@Cur NPs exhibited more effective inhibition of H22 cell
proliferation than p-PLGA@Cur NPs, which is thought to be because of enhanced endocytosis [42].
Collectively, these in vitro studies demonstrated that the RBCM-p-PLGA NPs are capable of efficiently
inhibiting H22 cell proliferation.
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3.4. Cellular Uptake In Vitro
LSM analysis was used to evaluate the uptake of FITC labeled nanoparticles into H22 cells
(Figure 4a). Strong FITC fluorescence appeared in the cells after incubation for 2 h with the
RBCM-FITC-p-PLGA NPs. In sharp contrast, minimal FITC fluorescence was seen in the case
of H22 cells treated with FITC-p-PLGA NPs. This is because both the RBCM coating on the NPs and
the cancer cell membrane comprise phospholipid bilayers, enhancing cell endocytosis of the former
over NPs lacking this coating. It appears that the RBCM coating was able to markedly enhance cellular
uptake of the NPs. 4T1 cells were used to verify this hypothesis, and again much greater uptake was
seen with the RBCM coated NPs (see Figure S3). The CLSM results obtained with RAW 264.7 cells
showed weak FITC fluorescence (Figure 4b) after incubation with the RBCM coated NPs, however,
and uptake here is much greater with the FITC-p-PLGA NPs. Cellular uptake is thus selective. The lack
of uptake by RAW 264.7 (macrophage) cells arises because the biomimetic NPs express CD47 proteins
from the RBCM at their exterior. These essentially mimic the surface properties of the host cell, so that
they can evade uptake by macrophages and send a “don’t eat me” signal to the host [43]. Hence,
the RBCM coating on the surface of the p-PLGA NPs can improve their biocompatibility.
For H22 cells, the ability of the RBCM coating to enhance cellular uptake of the NPs is borne
out by flow cytometry, which revealed that uptake of RBCM-FITC-p-PLGA NPs was around 1.6-fold
greater than that of FITC-p-PLGA NPs (Figure 5). The inverse was seen with RAW 264.7 cells, where
the uncoated NPs were taken up to a significantly greater extent than the RBCM-FITC-p-PLGA NPs
(Figure S4). It is hence clear that the RBCM coating allows the NPs to be selectively taken up by
cancerous cells and to evade phagocytosis by cells of immunity.
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3.5. In Vivo Antitumor Efficacy
The antitumor efficiency of the NPs was investigated in H22-tumor bearing ICR mice. The change
in tumor volume with time for mice given the different treatments is depicted in Figure 6a. The tumor
volume for the RBCM-p-PLGA@Cur treatment group was lower than any other treatment group.
Free Cur had relatively low efficacy, and at the end of the experimental period the tumor volume was
only reduced by ca. 49.7 ± 3.2% compared to the negative control group. The p-PLGA@Cur NPs led to
a tumor volume reduction of 72.3 ± 5.6%, while the RBCM-p-PLGA@Cur NPs led to an even greater
reduction (87.6 ± 4.5%). The tumor size with the RBCM-p-PLGA@Cur NPs is significantly lower than
with each of the other treatments (p < 0.005). It is thought that the RBCM coating on the surface of the
p-PLGA NPs could enhance uptake by cancer cells and the accumulation of the formulation in the
tumor. This is attributed to the erythrocyte membrane presenting the protein CD47, which allows the
NPs to send a “don’t eat me” signal to the host, avoiding phagocytosis and persisting in the systemic
circulation for an extended period of time [43].
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Changes in body weight were also monitored (Figure 6b). Free Cur treatment led to notably
decreased body weights, with the animal weights reduced by ca. 6.1 ± 1.2% at the end of the treatment
period. This indicates off-site toxicity and side effects arose. The mice in the NP treatment groups
experienced an increase in body weight with time, but this effect is smaller with the RBCM-p-PLGA@Cur
treatment group. The RBCM coating appeared to permit targeting to the tumor, thus avoiding systemic
toxicity from free Cur. Considering the saline group, the body weight of the mice increased significantly
over the experimental period, presumably because of the growth of the tumor. After sacrifice at the
end of the experiment, the tumors were excised and weighed (Figure 6c); the masses were in the order
saline > free Cur > p-PLGA@Cur NPs > RBCM-p-PLGA@Cur NPs. Again, the mass of the tumors in
the mice treated with the RBCM-coated NPs was significantly less (p < 0.05) than that seen with the
other treatment groups. This is in accordance with the in vivo tumor volume data.
Histological analysis to assess tumor cell apoptosis was performed using an immunofluorescent
TUNEL staining assay. The results are presented in Figure 7. In the animals that received pure Cur
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or the p-PLGA@Cur NPs, some green (apoptotic) cells were seen, but apoptosis was much more
evident in the RBCM-p-PLGA@Cur NP treatment group. These in vivo results clearly show that the
RBCM-p-PLGA@Cur NPs can act as an efficient drug delivery platform for tumor suppression.
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To investigate the in vivo safety and biocompatibility of the RBCM-p-PLGA@Cur NPs, the major
organs ( art, liver, sple n, lung, and kidneys) were recovered after sacrifice and ima ed after H&E
staining (Figure S5). No diff rence were observ d between the neg tive control group and the animals
receiving RBCM-p-PLGA@Cur NPs. The RBCM-p-PLGA@Cur NPs were hence determined to be
non-toxic and safe for s in vivo.
4. Discussion
The results obtained here add to the growing body of evidence showing that using the RBCM
as the exterior of NP delivery systems can increase the efficacy of anticancer therapeutics. Increased
circulation times are observed with RBCM-coated NPs, including those made of PLGA [44], and this
is expected to contribute to the in vivo efficacy of such systems. Qian et al. reported such an
extended half-life and reduced tumor volumes for hydrogel-encapsulating paclitaxel-loaded red blood
cell membrane nanoparticles [45], and Peng and co-workers noted analogous results with Prussian
blue/manganese dioxide NPs coated with the RBCM [46]. Gao et al. used perfluorocarbon-loaded
PLGA NPs coated with the RBCM to relieve hypoxia in the tumor and enhance radiotherapy, again
observing extended circulation times and reduced tumor volumes [14]. Other authors have applied
combined NP coatings containing both RBCM and cancer-cell membranes to doxorubicin-loaded CuS
nanoparticles, with similar findings i vivo [47].
The RBCM-p-PLGA NPs platform reported here integrates two distinct materials: a polymer and
a cell membrane, both of which play an importan role in determining the overall properties f the
co posite. A previous epor used the RBCM to coat docetaxel-lo ded PLGA NPs, but found that the
cumulative release of drug reached o ly ar und 20% after 72 h [48]. This is likely to be sub-optimal in
terms of therapeutic efficacy, with much of the drug remaining in the formulation and thus not being
therapeutically active. Our approach generated materials with a porous structure to overcome this
limitation, and extended release systems were thereby obtained after the RBCM coating.
The p-PLGA method proved to be an effective route to develop Cur-loaded NPs, and our
materials are superior to other Cur delivery systems in the literature. For instance, Dwivedi et al.
used a liquid-driven co-flow focusing process to fabricate Cur loaded PLGA NPs and obtained an
encapsulation efficiency of approximately 70% [49]. In addition, Jamali et al. used a nanoprecipitation
method to encapsulate Cur in PLGA NPs and the encapsulation efficiency and drug loading efficiency
were calculated to be 27% and 4.5%, respectively [50]. Our systems are notably improved in terms of
both encapsulation efficiency (>93.8%) and drug loading (>8%). Since all materials used to develop
the new DDS reported in this work are clinically used or highly biocompatible, the RBCM-p-PLGA NP
“artificial RBCs” should be able to act as safe and efficacious anticancer therapeutics.
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5. Conclusions
In this study, curcumin (Cur)-loaded porous PLGA nanoparticles were developed. These were
then cloaked with red blood cell membranes to prepare biomimetic platforms for targeted anticancer
therapies. The resultant RBCM-p-PLGA@Cur NPs are spherical and around 160 nm in size, eminently
suitable for uptake by cancer cells and retention in the tumor by means of the enhanced permeation
and retention effect. They additionally exhibit sustained release over 48 h. While the drug-free particles
were highly biocompatible (to both healthy and cancerous cells), the Cur loaded systems were effective
in killing cancer cells in vitro, and also enjoyed enhanced tumor cell uptake over p-PLGA@Cur NPs.
In contrast, the RBCM-coated NPs were not subject to phagocytosis by macrophage cells in vitro,
while the blank p-PLGA@Cur NPs were vulnerable to this process. In H22-tumor bearing mice, the
RBCM-p-PLGA@Cur NPs led to minimal systemic toxicity and clearly enhanced anti-cancer efficacy
(in terms of tumor volume/mass and the presence of apoptotic cells) compared to either free Cur or
p-PLGA@Cur NPs at an equivalent dose. The RBCM-p-PLGA@Cur NPs hence comprise a promising
nanocarrier for the targeted treatment of cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/9/429/s1,
Figure S1: A FESEM images of porous PLGA NPs prepared at 300 rpm. Pores are marked with red arrows,
Figure S2: UV-vis spectra of p-PLGA and p-PLGA@Cur NPs, Figure S3: CLSM images of 4T1 cells exposed to
FITC-p-PLGA and RBCM-FITC-p-PLGA NPs. Representative images from three independent experiments are
shown, Figure S4: Flow cytometry data for: (a) untreated RAW 264.7 cells and RAW 264.7 cells incubated for
4 h with FITC labeled (b) p-PLGA NPs or (c) RBCM-p-PLGA NPs. (d) The relative fluorescence intensity values
calculated from panels (a)–(c), Figure S5: H&E staining images (100×) of the major organs from H22 tumor-bearing
mice after treatment with saline or RBCM-p-PLGA@Cur NPs, Table S1: The results of Peppas analysis of the drug
release data.
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